RA PHARMACEUTICALS, INC.
RARX evidence brief
What we can confirm
- BioSniper Score:
- 7.2 / 10
- Lead Asset:
- ra101495 sc (Phase 2)
What it means
What to watch
Prepared research question
What matters most for RARX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
—
Cash Runway
—
Lead Asset
ra101495 sc (Phase 2)
Next Catalyst
—
Tracking 3 pipeline candidates · 6 clinical trials for RA PHARMACEUTICALS, INC..
Run RA PHARMACEUTICALS, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available RA PHARMACEUTICALS, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Phase 3
3 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Frequently asked questions
What is RA PHARMACEUTICALS, INC.'s lead drug candidate?
RA PHARMACEUTICALS, INC.'s most advanced tracked candidate is ra101495 sc (Phase 2) for Atypical hemolytic uremic syndrome (aHUS) and Lupus nephritis (LN).
Who is the CEO of RA PHARMACEUTICALS, INC.?
Contents Ra Pharmaceuticals is the chief executive officer of RA PHARMACEUTICALS, INC. (RARX).
What therapeutic areas does RA PHARMACEUTICALS, INC. focus on?
RA PHARMACEUTICALS, INC. develops therapies across Oncology, Rare Disease, Neurology, Immunology, Cardiovascular, Respiratory, Hematology, Nephrology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.